$6.82
1.77% yesterday
Nasdaq, May 20, 09:46 pm CET
ISIN
US89357L1052
Symbol
RNAZ
Sector
Industry

TransCode Therapeutics Inc Stock price

$7.01
-1.39 16.55% 1M
-303.64 97.74% 6M
-87.35 92.57% YTD
-1,092.55 99.36% 1Y
-1,485,784.99 100.00% 3Y
-2,956,792.99 100.00% 5Y
-2,956,792.99 100.00% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.31 4.63%
ISIN
US89357L1052
Symbol
RNAZ
Sector
Industry

Key metrics

Market capitalization $5.84m
Enterprise Value $-5.73m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.46
P/B ratio (TTM) P/B ratio 0.57
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-15.54m
Free Cash Flow (TTM) Free Cash Flow $-12.51m
Cash position $11.57m
EPS (TTM) EPS $-1,057.41
Short interest 0.17%
Show more

Is TransCode Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

TransCode Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast TransCode Therapeutics Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast TransCode Therapeutics Inc:

Buy
100%

Financial data from TransCode Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 0.44 0.44
21% 21%
-
-0.44 -0.44
21% 21%
-
- Selling and Administrative Expenses 4.56 4.56
13% 13%
-
- Research and Development Expense 10 10
12% 12%
-
-15 -15
12% 12%
-
- Depreciation and Amortization 0.44 0.44
21% 21%
-
EBIT (Operating Income) EBIT -16 -16
13% 13%
-
Net Profit -26 -26
50% 50%
-

In millions USD.

Don't miss a Thing! We will send you all news about TransCode Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

TransCode Therapeutics Inc Stock News

Neutral
PRNewsWire
13 days ago
15 patients treated across four escalating dose levels of TTX-MC138 No significant safety or dose limiting toxicities reported 10 patients remain on study with no evidence of disease progression PD analysis at 24 hours post-dosing provides evidence of miR-10b target engagement BOSTON , May 8, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to...
Neutral
PRNewsWire
15 days ago
BOSTON , May 5, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved an effective time at 12:01 a.m. Eastern Standard Time May 15, 2025, for its 1-for-28 reverse stock split.
Neutral
PRNewsWire
18 days ago
Split designed to achieve compliance with Nasdaq minimum bid price requirements BOSTON , May 2, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved a 1-for-28 reverse stock split. The reverse stock s...
More TransCode Therapeutics Inc News

Company Profile

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

Head office United States
CEO Thomas Fitzgerald
Employees 7
Founded 2016
Website www.transcodetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today